−12.20 MEUR
12.01 M
About GENEURO
Sector
Industry
CEO
Jesús Martin-Garcia
Website
Headquarters
Plan-les-Ouates
Employees (FY)
20
Founded
2006
ISIN
CH0308403085
FIGI
BBG00BWQN2D8
GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. It develops treatments against neurological disorders and autoimmune diseases. The firm's lead therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic human endogenous retroviruses (HERV) protein of the W family called pHERV-W env that has been identified as a factor in the onset and development of autoimmune diseases. The company was founded by Herve Perron and Jesus Martin-Garcia in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of GNRO is 1.445 EUR — it has decreased by 0.34% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange GENEURO stocks are traded under the ticker GNRO.
GENEURO is going to release the next earnings report on Sep 26, 2024. Keep track of upcoming events with our Earnings Calendar.
GNRO stock is 1.05% volatile and has beta coefficient of −0.27. Check out the list of the most volatile stocks — is GENEURO there?
One year price forecast for GENEURO has a max estimate of 4.000 EUR and a min estimate of 4.000 EUR.
Yes, you can track GENEURO financials in yearly and quarterly reports right on TradingView.
GNRO stock has fallen by 2.69% compared to the previous week, the month change is a 16.53% rise, over the last year GENEURO has showed a 26.28% decrease.
Today GENEURO has the market capitalization of 42.76 M, it has increased by 2.10% over the last week.
No, GNRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GNRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENEURO stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 20.00 employees. See our rating of the largest employees — is GENEURO on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENEURO technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENEURO stock shows the neutral signal. See more of GENEURO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on GENEURO future price: according to them, GNRO price has a max estimate of 4.00 EUR and a min estimate of 4.00 EUR. Read a more detailed GENEURO forecast: see what analysts think of GENEURO and suggest that you do with its stocks.